News & Updates
Filter by Specialty:
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
12 Aug 2022
1 week off methotrexate works okay for RA patients receiving flu shot
Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.
1 week off methotrexate works okay for RA patients receiving flu shot
11 Aug 2022
Men with PsA derive more benefit from MTX+ETN therapy than women
Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.
Men with PsA derive more benefit from MTX+ETN therapy than women
09 Aug 2022
Apremilast more efficacious in PsA patients with moderate vs high disease activity
Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.
Apremilast more efficacious in PsA patients with moderate vs high disease activity
22 Jul 2022
6-month secukinumab use improves outcomes in psoriatic arthritis
Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.
6-month secukinumab use improves outcomes in psoriatic arthritis
21 Jul 2022
Which factors predict hospitalization for acute gout?
Several factors, including older age, overnight emergency department (ED) arrival time, higher serum urate (SU), higher C-reactive protein (CRP), and higher total white cell count at presentation, predict hospitalization for acute gout, according to a study.
Which factors predict hospitalization for acute gout?
21 Jul 2022
Smoking, comorbidities, EAMs up death risk in hospitalized ankylosing spondylitis patients
Smoking, extra-articular manifestations (EAMs), and comorbidities are all associated with a higher risk of all-cause mortality in hospitalized patients with ankylosing spondylitis (AS) than those in the comparison cohort, reports a study.
Smoking, comorbidities, EAMs up death risk in hospitalized ankylosing spondylitis patients
20 Jul 2022
Older age, lower BMI, seropositivity tied to RA-related bronchiectasis
Isolated bronchiectasis (BR) in rheumatoid arthritis (RA) that is not caused by interstitial lung disease (ILD) is associated with seropositivity, older age at RA diagnosis, and lower body mass index (BMI) at RA onset, a recent study has found.